Marginal Zone Lymphomas

Speakers: Catherine Thieblemont

Catherine Thieblemont is professor of Haematology in the Paris University, chair of the Lymphoma group at Hospital Saint-Louis, and head of the hemato-oncology department, chair of the Lymphoma group at Hospital Saint-Louis, and head of the hemato-oncology department-Paris, France

Prof Thieblemont 's major interest is the biological and clinical features of lymphomas. She is involved in clinical trials for the treatment of lymphoma patients, particularly integrating innovative treatments in new strategies based on targeted therapies, cell immunotherapies and CAR T-cells. She is also involved in programs developing genomic and metabolomic studies in refractory high-grade lymphomas, to determine biological key targets.

Prof Thieblemont is an active member of the Lymphoma Study Association (LYSA), a cooperative group of French and Belgian physicians interested in the treatment of lymphomas. Within the LYSA, she is one of the members of the steering committee and the scientific committee, and she is coordinating the subcommittee of the marginal zone lymphoma. She is an active member of the International extranodal Lymphoma study group (IELSG) as of one the members of the board director.